Stock data
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC) reported net income of -US$32.77M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$34.40M | -US$32.77M | — |
| 2024 | — | — | -US$26.68M | -US$24.44M | — |
| 2023 | — | — | -US$21.27M | -US$19.38M | — |
| 2022 | — | — | -US$14.00M | -US$13.68M | — |
| 2021 | — | — | -US$13.65M | -US$13.59M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$10.14M | — |
| 2026-03-31 | — | -US$10.04M | — |
| 2025-12-31 | — | -US$8.74M | — |
| 2025-09-30 | — | -US$8.62M | — |
| 2025-06-30 | — | -US$7.70M | — |
| 2025-03-31 | — | -US$7.71M | — |
| 2024-12-31 | — | -US$7.90M | — |
| 2024-09-30 | — | -US$6.27M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.